文献速递功能神经外科

立体定向放射外科囊切开术与常规治疗对难治性强迫症的成本效果分析

Cost-effectiveness analysis of radiosurgical capsulotomy versus treatment as usual for treatment-resistant obsessive-compulsive disorder.
PubMed 文献 · J Neurosurg · 2022-07-29

该研究采用决策分析模型,比较立体定向放射外科囊切开术(SRS-C)与常规治疗(TAU)对难治性强迫症(TROCD)的成本效果,数据来自9项研究共158例患者。结果显示SRS-C更具成本效果,增量成本效果比为每获得一个质量调整生命年28960美元。

要点

  • SRS-C组3年内净获得的质量调整生命年较TAU组多0.27(95%CI 0.2698-0.2702,p<0.0001)。
  • 在每质量调整生命年5万和10万美元的支付意愿阈值下,SRS-C在83%和100%的模拟迭代中更具成本效果。
  • SRS-C的增量成本效果比为每获得一个质量调整生命年28960美元。

核心结论

  • 与常规治疗相比,立体定向放射外科囊切开术对难治性强迫症在多种可能的成本和效果值下更具成本效果。

研究设计与样本

  • 决策分析模型,比较SRS-C与TAU对TROCD的成本效果。
  • 治疗反应和并发症率来自相关临床试验的综述。
  • 成本从医疗保健部门角度,采用Medicare报销率和可获得的卫生经济学数据。
  • 进行蒙特卡洛模拟和概率敏感性分析以估计增量成本效果比。
  • 模型纳入9项研究中共158例接受SRS-C且随访至少36个月的TROCD患者。

主要发现

  • SRS-C相比TAU更具成本效果,增量成本效果比为每获得一个质量调整生命年28960美元。
  • 3年时间范围内,SRS-C组净获得的质量调整生命年较TAU组多0.27(95%CI 0.2698-0.2702,p<0.0001)。
  • 在每质量调整生命年5万和10万美元的支付意愿阈值下,蒙特卡洛模拟显示SRS-C在83%和100%的迭代中分别比TAU更具成本效果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Stereotactic radiosurgical capsulotomy (SRS-C) is an effective neurosurgical option for patients with treatment-resistant obsessive-compulsive disorder (TROCD). Unlike other procedures such as deep brain stimulation and radiofrequency ablation, the cost-effectiveness of SRS-C for TROCD has not been investigated. The authors herein report the first cost-effectiveness analysis of SRS-C for TROCD. METHODS: Using a decision analytic model, the authors compared the cost-effectiveness of SRS-C to treatment as usual (TAU) for TROCD. Treatment response and complication rates were derived from a review of relevant clinical trials. Published algorithms were used to convert Yale-Brown Obsessive Compulsive Scale scores into utility scores reflecting improvements in quality of life. Costs were approached from the healthcare sector perspective and were drawn from Medicare reimbursement rates and available healthcare economics data. A Monte Carlo simulation and probabilistic sensitivity analysis were performed to estimate the incremental cost-effectiveness ratio. RESULTS: One hundred fifty-eight TROCD patients across 9 studies who had undergone SRS-C and had at least 36 months of follow-up were included in the model. Compared to TAU, SRS-C was more cost-effective, with an estimated incremental cost-effectiveness ratio of $28,960 per quality-adjusted life year (QALY) gained. Within the 3-year time horizon, net QALYs gained were greater in the SRS-C group than the TAU group by 0.27 (95% CI 0.2698-0.2702, p < 0.0001). At willingness-to-pay thresholds of $50,000 and $100,000 per QALY, the Monte Carlo simulation revealed that SRS-C was more cost-effective than TAU in 83% and 100% of iterations, respectively. CONCLUSIONS: Compared to TAU, SRS-C for TROCD is more cost-effective under a range of possible cost and effectiveness values.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Najera RA, Gregory ST, Shofty B, et al. Cost-effectiveness analysis of radiosurgical capsulotomy versus treatment as usual for treatment-resistant obsessive-compulsive disorder. J Neurosurg. 2022. PMID: 35907186. doi:10.3171/2022.5.JNS22474

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。